Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings Of The Fortnight: Crossover Investors Key To Intarcia’s Massive $210 Million Series C Round

This article was originally published in The Pink Sheet Daily

Executive Summary

Plus news on recent financings by Visterra, AbbVie, Pearl Therapeutics and Auspex.

You may also be interested in...



Intarcia Forgoes Partnerships, Raises $210M In Equity And Debt Instead

Rather than partner its implantable formulation of exenatide, the biotech turned to hedge funds and other non-traditional investors for the year’s largest round of private capital. The deal enables Intarcia to begin Phase III trials on lead program ITCA-650 for type 2 diabetes, which it believes could be a blockbuster.

Auspex Secures $25M To Get To NDA

The biotech garnered a $25 million Series D round, which could be enough to propel it through a Phase III trial and to FDA with its lead candidate. Investors are hoping an approved product could make Auspex an attractive take-out candidate.

Ziarco Picks Up Pfizer Assets, Series A Round

A former Pfizer VP used four of the pharma’s programs to secure private financing from an unlikely investor and got the pharma to buy into the new start-up. Now, he hopes to develop next generation treatments for inflammatory and allergic diseases.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS073511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel